Düşük doz Methotrexatın indüklediği Henoch-Schönlein Purpurası

Abstract

Metotreksat (MTX), çeşitli malignite ve kronik inflamatuvar hastalıkların tedavisinde kullanılan antiproliferatif bir folik asit antagonistidir. Düsük doz, haftalık MTX tedavisi alan hastalarda sık görülen yan etkiler bulantı ve stomatittir. Henoch-Schönlein purpurası (HSP) genellikle, infeksiyon ajanları, soğuk, böcek ısırması, besinler veya ilaçlara bağlı olarak tetiklenir. Bu yazıda juvenil idiyopatik artrite yönelik düşük doz metotrexate başlanan 14 yaşındaki erkek hastada tedavinin 3. haftasında ortaya çıkan HSP literatür eşliğinde sunulmuştur. 

Keywords

• Henoch-Schönlein Purpura,Juvenile Idiopathic Artrit,Metotreksa

Henoch-Schönlein Purpura induced by Low-Dose Methotrexate

Abstract

Methotrexate (MTX) is an antiproliferative folic acid antagonist used in the treatment of various malignancies and chronic inflammatory diseases. Commonly observed side effects in patients receiving lowdose, weekly MTX treatment are nausea and stomatitis. Henoch-Schönlein purpura (HSP) is a condition generally induced by infectious agents, exposure to cold, insect bites, foods, and drugs. In this paper, we presented together with a review of the literature a case of HSP that developed in the third week of treatment of a 14-year-old male patient started on low-dose methotrexate for juvenile idiopathic arthritis. 

Keywords

• Henoch-Schönlein Purpura,Juvenile Idiopathic Arthritis,Methotrexate

References

1. 1) MacGinnitie AJ, Walensky LD, Turvey SE. Management of an anaphylactoid reaction to methotrexate with a stepwise graded challenge. Pediatr Allergy Immunol 2003;14 (2):409-11. 2) Goerttler E, Kutzner H, Peter HH, Requena L. Methotrexate-induced papular eruption in patients with rheumatic diseases: a distinctive adverse cutaneous reaction produced by methotrexate in patients with collagen vascular diseases. J Am Acad Dermatol 1999;40 (3):702-7. 3) Ozen S. The spectrum of vasculitis in children. Best Pract Res Clin Rheumatol 2002;16 (5):411-25. 4) Tizard EJ. Henoch-Schönlein purpura. Arch Dis Child 1999;80/3):380-83. 5) Bruce N Cronstein, MD.The mechanism of action of methotrexate. Rheum Dis Clin N Amer 1997; 23 (2):739- 55. 6) Van Ede AE, Laan RFJM,. Rood MJ et al. Effects of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheumatism 2001;44 (3):1515-24. 7) Masuda M, Nakanishi K, Yoshizawa N. Group A streptococcal antigen in the glomeruli of children with Henoch-Schonlein nephritis. Am J Kidney Dis 2003;41 (3):366-70. 8) Edekmann CM Jr, Bernstein J, Meadow SR, Spitter A, Travis LB. Schonlein-Henoch Syndrome. In: Pediatric Kidney Disease, (2nd edition), Little, Brown and Company 1992;1525-33. 9) Ozlem A, Birsev K. Intoxication Due to High Dose Methotrexate in a Patient with Rheumatoid Arthritis: ACase Report. Turk J Rheumatol 2011;26(1):58-60.